Clinical Trials in Frederick, Maryland

5 recruiting

Showing 116 of 16 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled576 locationsNCT03866382
Recruiting
Phase 2Phase 3

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Non-small Cell Lung Cancer
BioNTech SE1,260 enrolled184 locationsNCT06712316
Recruiting
Phase 3

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled303 locationsNCT07174336
Recruiting
Phase 3

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Not Applicable

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Breast CancerCognitive Impairments
NRG Oncology386 enrolled680 locationsNCT05896189
Recruiting
Phase 3

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled829 locationsNCT05812807
Recruiting
Phase 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled288 locationsNCT06868277
Recruiting
Phase 3

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Phase 3

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
BioNTech SE621 enrolled138 locationsNCT06712355
Recruiting

GEMINI-NSCLC: NSCLC Biomarker Study

Tempus AI1,200 enrolled58 locationsNCT05236114
Recruiting
Phase 3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Gilead Sciences1,514 enrolled288 locationsNCT05633654
Recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Breast Cancer
Exact Sciences Corporation1,800 enrolled58 locationsNCT06401421
Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

CancerBladder CancerImmunotherapy+1 more
Elephas2,000 enrolled8 locationsNCT07327489
Recruiting

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

NSCLC (Non-small Cell Lung Cancer)Metastatic NSCLC - Non-Small Cell Lung Cancer
Elephas200 enrolled7 locationsNCT05478538
Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Breast Cancer
Agendia30,000 enrolled134 locationsNCT03053193